METHODS: A total of 110 ARDS patients with VAP were randomly divided into an experimental group and control group. The control group received routine nursing while the experimental group received ICU nursing risk management combined with the cluster nursing model to compare the clinical efficacy in the two groups of patients.
RESULTS: There were no significant differences in general information (P>0.05). The total clinical effective rate of patients in the experimental group was significantly higher than that of the control group (P<0.05). The Acute Physiology and Chronic Health Evaluation (APACHE II) scores of all patients after nursing were significantly lower than those before nursing (P<0.001), and the APACHE II score in the experimental group after nursing was significantly lower than that in the control group (P<0.001). The interleukin-8 (IL-8), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α) levels of all patients after nursing were significantly lower than those before nursing (P<0.001), and the levels in the experimental group after nursing were significantly lower than those in the control group (P<0.001). The vital capacity (VC), total lung capacity (TLC), and forced expiratory volume 1 second (FEV1)/forced vital capacity (FVC) levels of all patients after nursing were significantly higher than those before nursing (P<0.001), and the levels in the experimental group after nursing were significantly higher than those in the control group (P<0.001). The MOS 36-item short form health survey (SF-36) scores of all patients after nursing were significantly higher than those before nursing (P<0.001), and the scores in the experimental group after nursing was higher than that in the control group (P<0.001).
CONCLUSIONS: ICU nursing risk management combined with the cluster nursing model can effectively and significantly reduce inflammatory reactions, improve pulmonary function, and enhance the quality of life of ARDS patients with VAP, making it worthy of promotion and application.
BACKGROUND: Chinese Clinical Trial Registry ChiCTR2100048112.